Esperion Therapeutics’ (ESPR) “Buy” Rating Reaffirmed at HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $16.00 price target on the biopharmaceutical company’s stock.

ESPR has been the subject of a number of other research reports. StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Cantor Fitzgerald started coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target on the stock. The Goldman Sachs Group began coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective for the company. JMP Securities reissued a “market outperform” rating and set a $7.00 price objective on shares of Esperion Therapeutics in a report on Thursday, January 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Esperion Therapeutics in a research note on Friday, December 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Esperion Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $6.75.

Esperion Therapeutics Price Performance

Shares of NASDAQ:ESPR opened at $1.88 on Tuesday. The firm has a fifty day moving average price of $2.28 and a two-hundred day moving average price of $2.12. The company has a market cap of $370.44 million, a price-to-earnings ratio of -2.94 and a beta of 1.01. Esperion Therapeutics has a one year low of $1.58 and a one year high of $3.94.

Institutional Trading of Esperion Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ESPR. Public Employees Retirement System of Ohio purchased a new position in shares of Esperion Therapeutics in the 3rd quarter worth $606,000. Anson Funds Management LP purchased a new position in Esperion Therapeutics in the third quarter worth about $540,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Esperion Therapeutics by 71.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after purchasing an additional 295,378 shares during the period. Wellington Management Group LLP increased its position in shares of Esperion Therapeutics by 66.8% during the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock valued at $995,000 after purchasing an additional 241,512 shares during the last quarter. Finally, Wasatch Advisors LP boosted its holdings in shares of Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after buying an additional 6,483,070 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.